Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2018

EFFECTS OF THE NA-CL CO-TRANSPORTER (NCC) IN WESTERN
DIET INDUCED METABOLIC AND CARDIAC DYSFUNCTION
Zachary S. Cutter
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Cardiology Commons, Cardiovascular Diseases Commons, Circulatory and Respiratory
Physiology Commons, and the Translational Medical Research Commons
© Zachary Cutter

Downloaded from
https://scholarscompass.vcu.edu/etd/5431

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

EFFECTS OF THE NA-CL CO-TRANSPORTER (NCC) IN WESTERN DIET INDUCED
METABOLIC AND CARDIAC DYSFUNCTION
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University

by
ZACHARY SAMUEL CUTTER
B.S. Kinesiology, James Madison University, 2014

Director: STEFANO TOLDO, PH.D.
Assistant Professor
Department of Internal Medicine
Division of Cardiology
Department of Physiology and Biophysics

ii
Acknowledgements
My search for continued education led me Graduate School at Virginia Commonwealth
University, a place whose libraries and laboratories I have called a second home for
nearly two years. The learning experiences here have cemented a curiosity for intellect
and allowed me to express and embrace my passions. I would be remiss if I did not
acknowledge and thank those who have contributed mightily to my educational
experiences.

Dr. Stefano Toldo, thank you for opening your home and laboratory doors to me,
showing me research ethics and techniques, and being a role model for how to
approach and investigate the complex world of cardiovascular physiology.

Dr. Antonio Abbate, thank you for setting a strong example for how to evaluate a
problem, ask the right questions, and approach basic science research with the clear
goal of therapeutic application in patients.

Dr. Adolfo Mauro, thank you for your skill in teaching me hands-on techniques in the
laboratory and for your patience in answering many of my questions, especially those
after the lights went off in MMRB.

Dr. Eleonora Mezzaroma, thank you for keeping a young researcher on his toes and
coordinating all of the moving pieces of this outstanding laboratory.

The entirety of the basic science and clinical laboratory group, thank you for our
biweekly laboratory meetings that foster a melting pot of ideas and showing me how a
connected group of research minds can truly impact medicine.

My family, thank you for your unwavering support in all aspects of my life to help me
take the steps to reach my goals.

iii
Table of Contents

Abstract: ......................................................................................................................... v
Introduction: .................................................................................................................. 1
Obesity: Prevalence, Classification, and Health Risks ................................................. 1
Heart Failure: Definitions, pathophysiology, and paradoxical prognosis with obesity .. 3
Inflammation: obesity derived and heart failure mediator ............................................. 8
IL-18: Production and Signaling ................................................................................. 11
IL-18: Functions ......................................................................................................... 16
Role of IL-18 in the Immune System ....................................................................... 16
Role of IL-18 in the Cardiovascular System: Health and Disease .......................... 18
Role of IL-18 in metabolism: Health and Disease ...................................................... 26
Similarities and differences in IL-18KO and IL-18RαKO mouse phenotypes: A role for
the Na-Cl Co-transporter? .......................................................................................... 28
Methods ....................................................................................................................... 33
a.

Animals................................................................................................................ 33

b.

Study Design ....................................................................................................... 33

c.

Food intake and body weight ............................................................................... 35

d.

Oral Glucose Tolerance Test (OGTT) ................................................................. 35

e.

Insulin Tolerance Test (ITT) ................................................................................ 36

f.

Echocardiography ............................................................................................... 37

g.

IL-18 ELISA ......................................................................................................... 37

h.

Statistical Analysis ............................................................................................... 38

Results: ........................................................................................................................ 39
WD induces systemic release of active IL-18............................................................. 39
Body Weight changes over study duration ................................................................. 40
WD induced Type II Diabetic phenotype .................................................................... 42
Echocardiographic assessment of systolic, diastolic, and global function .................. 43
Discussion ................................................................................................................... 45
References ................................................................................................................... 54

iv
List of Figures
Figure 1. Heart Failure Incidence with Obesity ................................................................ 2
Figure 2. Differing cardiac insults lead to a spectrum of geometric and functional
changes. .......................................................................................................................... 5
Figure 3. Mortality in Obese HF patients. ........................................................................ 7
Figure 4. Inflammation from adipocytes. ....................................................................... 10
Figure 5. IL-18 Activation and Release ......................................................................... 12
Figure 6. IL-18 Binding and Signaling. .......................................................................... 15
Figure 7. Hypertrophic Adaptation and IL-18. ................................................................ 19
Figure 8. Atherosclerosis and IL-18............................................................................... 21
Figure 9. IL-18 and diastolic dysfunction.. ..................................................................... 25
Figure 10. IL-18KO and IL-18RKO divergence. ............................................................ 28
Figure 11. NCC in Atherosclerosis.. .............................................................................. 30
Figure 12. IL-18 Physiology. .......................................................................................... 31
Figure 13. Hypothesis Schematic. ................................................................................. 32
Figure 14. Research Design .......................................................................................... 34
Figure 15. WD Increases circulating IL-18 .................................................................... 39
Figure 16. Increased Body Weight Gain of IL-18KO and NCCKO mice on WD. ........... 41
Figure 17. Differences in fasting glycemia before, but not after WD. ............................ 42
Figure 18. Attenuated changes in cardiac function after WD in IL-18KO and NCCKO
mice............................................................................................................................... 44

List of Tables
Table 1. BMI classifications ............................................................................................. 1
Table 2. WD Composition. ............................................................................................ 34

v
Abstract

EFFECTS OF THE NA-CL CO-TRANSPORTER (NCC) IN WESTERN DIET INDUCED
METABOLIC AND CARDIAC DYSFUNCTION
Zachary S. Cutter
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2018.

Major Director: STEFANO TOLDO, PH.D. Assistant Professor Department of Internal
Medicine, Division of Cardiology, Department of Physiology and Biophysics

Obesity and heart failure are increasingly known as pro-inflammatory states that
carry a significant and debilitating health burden. High-fat diets represent a common
pathogenic route to obesity and future development of heart failure. Interleukin-18, a proinflammatory cytokine, has been identified as essential for metabolic and glucose
homeostasis; however also mediates cardiac dysfunction, in particular diastolic
dysfunction. A divergence of mouse IL-18KO and IL-18RKO metabolic phenotypes have
been shown and, additionally, the Na-Cl Co-transporter (NCC) has recently been
identified as a novel receptor for IL-18. Therefore, we hypothesized that NCC mediates
the IL-18 induced positive metabolic and negative cardiac effects. Using male C57BL/6J
mice, we evaluated metabolic and cardiac function changes in wild-type, IL-18KO, and
NCCKO mice after at least 8 weeks of high saturated-fat and high sugar diet (Western
Diet, WD). This was accomplished by measurements of body weight gain, fasting
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glucose, and cardiac systolic and diastolic function parameters. We report NCCKO mice
had a significantly increased body weight gain compared to baseline vs. wild-type mice
(55% vs. 22%). Additionally, NCCKO mice had a lower percent worsening from baseline
in isovolumetric relaxation time (IRT) (29% vs. 123%) and Tei Index (62% vs. 162%) vs.
wild-type mice (P<0.05). Collectively, the metabolic and cardiac changes in NCCKO mice
after WD resembled those of IL-18KO mice on the same diet. The Na-Cl Co-transporter
may function to mediate metabolic and cardiac effects of IL-18 during high-fat diet feeding
and its possible role in doing so warrants further investigation.

Introduction:
Obesity: Prevalence, Classification, and Health Risks
Combinations of poor quality diet, sedentary lifestyle, smoking, and socioeconomic
status continue to cause and be associated with the frightening prevalence of obesity,
where 37.7% of adults and 17.2% of youth in the United States were obese (BMI ≥30) in
2014 (1,2). Although burdened by its limitations in finely discriminating between body fat
% and lean mass (3,4), body mass index, (BMI, calculated as weight in kilograms divided
by height in meters squared) for the time being remains the conventional measure used
in broad population studies to evaluate body composition due to its ease in obtaining and
reproducibility. Before understanding potential health implications of obesity, it is
important to define the spectrum of BMI classifications. As indicated in Table 1, the
calculated value of a patient’s BMI stratifies them into defined groupings where increases
in BMI are labeled as worsened obesity.

Table 1. BMI classifications
Body Mass Index (BMI) classification

kg/m2

Underweight

Normal

Overweight

Obese

Class II
Obesity

Class III
Obesity

<18.5

18.5-24.9

25-29.9

30-34.9

35-39.9

>40
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Depicted in Figure 1, a J or U-shaped curve exists correlating BMI to risk of
mortality; where a BMI classification that is either lower than normal or obese carries with
it an increased risk of all-cause mortality (5, 6). The risk for cardiovascular diseases also
exhibit similar trends with BMI. When stratified into normal, overweight, or obese BMI it is
apparent that obesity is associated with higher risk of future development of heart failure.
In fact, for each 1 increment increase in BMI, the risk of heart failure increases 5% for
men and 7% for women (7). This evidence clearly places obesity (BMI>30 kgm-2) as a risk
factor for development of heart failure.

A.

B.

Figure 1. Heart Failure Incidence with Obesity: Adapted from Adams et al, NEJM, 2006. Relationship
of BMI to relative risk of death compared to the reference group (BMI 23.5-24.9) with respect to age
groups (A). Adapted from Kenchaiah et al, NEJM, 2002. Increase incidence of heart failure with
increasing BMI in aging women and men (B).
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Heart Failure: Definitions, pathophysiology, and paradoxical prognosis with
obesity
Normally, the heart and the vasculature are able to adapt and supply adequate
amounts of oxygenated blood to match increased physiological demands of the body.
When the heart is unable to supply sufficient oxygenated blood to match systemic needs,
whether at baseline or during exertion, and symptoms of shortness of breath, dyspnea on
exertion, fatigue, or exercise intolerance become clinically apparent, a patient is
diagnosed with the syndrome of heart failure. Echocardiographic assessment of cardiac
function is essential to evaluating a patient’s status, future prognosis, and tracking of
medical management. Ejection Fraction (EF, %) is a calculated value derived from the
difference in volume estimations at end diastole (EDV) and end systole (ESV) of the
cardiac cycle ([EDV-ESV]/EDV]*100) that is used to evaluate aspects of cardiac
contractile function. Population based studies have helped establish normal reference
values for EF where guidelines refer to a normal EF for an adult to be 62% with a 2
standard-deviation range to be 52-72% (8).
While proper contractile function of the heart is undeniably essential, the ability of
the heart to relax and properly fill (diastole) with blood before the next ejection is just as
functionally important. The filling capacity of the heart is derived from two processes:
active re-uptake of intracellular calcium that initiates the relaxation process and the ability
of myocardium to stretch as one functional unit to accommodate the reception of blood
from the atria. Impairments in contractility, relaxation, or compliance can lead to a
decrease in systemic output of oxygenated blood and heart failure.
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Essential to a diagnosis of heart failure is the presence of symptoms. After systolic
and/or diastolic dysfunction manifests symptomatically and an echocardiographic
assessment has been completed, a patient is grouped into a certain classification of heart
failure based on ejection fraction. If calculated EF is <40% that patient is diagnosed with
heart failure with reduced ejection fraction (HFrEF), whereas a patient with calculated EF
≥50% is diagnosed with heart failure with preserved ejection fraction (HFpEF) ( 9).
Additionally, an EF between the two cut-off values (40-49%) places an individual in a
heart failure with mid-range ejection fraction (HFmrHF); however, this is a novel category
that is still under investigation (9). The larger divisions of heart failure diagnosis (HFrEF
vs. HFpEF) both encompass a heart that is unable to meet systemic needs; however, the
mechanism and etiology of the different diagnosis are mixed, with some features common
to both, and others that predominate in one or the other.
Whereas an ischemic insult results in an intense local immune response that
extends myocyte loss, ventricular chamber dilation, and systolic impairment (classic of
HFrEF), the consequence of comorbidities as T2D, obesity, and a poor-quality diet that
result in a low grade state of inflammation contribute to ventricular hypertrophy, stiffness,
increased filling pressures, overt diastolic dysfunction and a restricted/hypertrophied
ventricular cavity (more classic of HFpEF, Figure 2) (32,33). Despite the differing original
insult to the myocardium, a common feature of both heart failure classifications is
supranormal inflammation that alters cardiac structure and function in one form or
another. Thus, greater understanding of the intricate biology of inflammation within the
context of metabolic and cardiac dysfunction is essential.
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Figure 2. Differing cardiac insults lead to a spectrum of geometric and functional changes.
Progression of cardiac structure and function based on differing initial insults. Acute ischemic damage
(right) causes rapid and widespread myocyte cell death that sparks an intense local immune response.
Secondary loss of nearby functional myocytes due to immune activation amplifies local damage. Ventricular
volume increases in a Frank-Starling mechanism to increase preload to compensate for poor contractility,
culminating in dilated LV and systolic dysfunction. Chronic systemic inflammation stemming from
multifactorial combinations of aging, poor quality diet, obesity, and Type II Diabetes (T2D) (left) can cause
myocyte hypertrophy and stiffness that restrict the ventricle’s ability to relax and reduce ventricular tissue
compliance resulting diastolic dysfunction.
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Epidemiologic studies to estimate new and total cases of a disease on a population
scale serve to evaluate disease burden placed on the collective health care system and
members. A recent population study evaluating the decade of 2000—2010 discovered a
decline in incidence of overall heart failure diagnosis; however a categorical shift in
incidences occurred. HFrEF reduced to a greater degree than HFpEF to the point that
HFpEF is making up a larger proportion of new heart failure cases (10, 11). Problematic to
this rise in HFpEF is the nearly matching high mortality rate at 5 years with HFrEF (65%
vs. 68% respectively), and the disconnect that current therapeutic options for HFrEF
patients do not appear to improve mortality in HFpEF patients (12,13). Perhaps due to the
multifactorial nature of heart failure including aging, obesity, and hypertension that are
exhibiting parallel prevalence increases, the overall prevalence of heart failure continues
to rise in the United States (11).
Although established that obesity increases the risk of developing heart failure,
after the onset of heart failure there in fact may be a survival benefit associated with being
obese. Depicted in Figure 3, multiple studies have replicated this paradoxical finding of
lowest mortality in heart failure patients to be patients that are obese (BMI 30-34.9 kg/m2)
(14–18). This apparent relationship is complex, but some varying hypothesis exist in
attempts to explain this phenomenon including: a metabolic “reserve” that benefits obese
patients during the catabolic state of heart failure, increased skeletal muscle mass,
increased levels of adipocyte derived anti-inflammatory/insulin-sensitizing proteins (19),
decreased sympathetic nervous system activation (20), or earlier identification of disease
and better tolerance of protective medications (21). Interestingly, the paradox appears to
be more apparent in patients with low cardiorespiratory fitness, with low CRF obese
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patients again having improved survival over low CRF normal BMI patients (22). Although
unclear, the biological mechanisms that contribute to outcomes in patients with coexisting metabolic and cardiac dysfunction certainly warrant further investigation.

Figure 3. Mortality in Obese HF patients. Adapted from Horwich et al JACC 2001, Curtis et al JAMA
2005, and Oreopoulos et al AHJ 2008. Differing representations of improved survival in obese (BMI ≥
30kg/m2) patients that have diagnosed heart failure.
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Inflammation: obesity derived and heart failure mediator
The numerous adverse effects of obesity for development of morbid conditions
including Type II Diabetes (T2D), coronary artery disease, heart failure, cancer, and more
have been noted for decades. Elucidation of exact chronologic events that initiate a path
toward obesity and end with a co-morbid condition have been elusive, but our
understanding of changes in physiology during obesity have expanded.
The overlap of metabolic and immune system functions to homeostasis indicate
that perturbations of one can have a maladaptive domino effect on the other. Individual
observations in the clinic and within entire populations have depicted a clear connection
between metabolic dysfunction and immune responses. Increases of BMI (overweight
and obese) in men and women are positively associated with increased levels of highsensitivity C-Reactive Protein (hs-CRP), a protein secreted by the liver in response to
stress or injury that functions to augment acute innate immune activity (23). These
observations have led to the catch-phrase describing obesity as a state of “low-grade
chronic inflammation.”
When the balance of energy intake exceeds energy expenditure, due to any
combination of increased whole caloric consumption, increased dietary energy density
from higher saturated fat composition, or decreased physical activity, the capacity of
adipose tissue to store the energy is exceeded. Due to the fact that adipose tissue is
composed of a mix of adipocytes, networks of endothelial and smooth muscle cells, and
resident macrophages and T-cells, changes in the integrity of adipocytes are rapidly
sensed and transmitted systemically (24). Overwhelming the adipose storage depot leads
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to a detrimental cycle of adipocyte dysfunction and immune activation with whole body
negative implications.
Depicted in Figure 4, multiple hypothesis exist for how adipocyte dysfunction
manifests with subsequent immune activation and eventual metabolic dysfunction.
Included are synergistic activity of adipocyte-derived cytokines, free fatty acid (FFA)
release, endoplasmic reticulum (ER) and oxidative stress, and hypoxia from outgrowing
local vascular supply (25). Prolonged adipocyte and immune cell shifts toward proinflammatory routes participate in local and systemic impairment of insulin sensitivity and
glucose utilization, hallmarks of T2D and metabolic syndrome (26).
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Figure 4. Inflammation from adipocytes. (Top) Adapted from Heredia et al Proceedings of the Nutrition
Society 2012, Mechanisms for how adipocyte dysfunction communicates with local macrophages to
perpetuate a state of inflammation that lead to insulin resistance. (Bottom) Adapted from Ouchi et al
Nature Reviews: Immunology 2011, Development of obesity changes adipose tissue morphology and
composition toward a milieu of pro-inflammatory cytokines and adipokines that derail homeostatic
metabolism.
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After growing evidence of increased cytokines such as TNF-α, IL-6, and other
inflammatory components such as hs-CRP directly associated with increased heart failure
incidence and worsening heart failure functional classification, it became apparent that
the presence of inflammation in heart failure patients could be valuable targets to predict
outcomes (27–29). Basic science observations of cytokines, such as TNF-α, IL-1β, and IL18, causing ventricular remodeling, myocyte hypertrophy, decreasing contractility, and
inducing apoptosis pushed the role of inflammation from association toward causative in
the pathogenesis of heart failure (30–33). Discussed further is a major component of
inflammation, Interleukin-18, and its contributions to immune, cardiovascular and
metabolic function.

IL-18: Production and Signaling
Since first implicated in 1989 as a soluble factor that, in combination with IL-12,
induced Interferon-γ in a mouse model of endotoxemia, our understandings of the
signaling and function of Interleukin-18 in human physiology and pathophysiology have
expanded (34). The Interleukin-1 family of cytokines, now encompassing 11 proteins of
varying homology including IL-1β and IL-18, have been extensively studied for how they
contribute to coordination of immune response. Unlike its IL-1 family member IL-1β, the
human chromosome 11 and murine chromosome 9 gene product IL-18 has been
identified to be constitutively expressed in human peripheral blood mononuclear cells
(PBMCs, including T cells, B cells, natural killer (NK) cells and monocytes) as well as
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endothelial cells, keratinocytes, osteoblasts, dendritic cells, astrocytes, microglia and gut
epithelial cells (35,36). Depicted in Figure 5, The 24kD 193 amino acid product is
synthesized without an endoplasmic reticulum signaling peptide, does not contain Nglycosylation sites, and remains inactive in the cytosol until cleavage by the cysteine
protease Caspase-1 creates the 17kD 157 amino acid active form to be secreted out of
the cell via plasma membrane pore or released by membrane rupture (37–40).

IL-18
IL-18

Activated
Inflammasome
& Caspase-1

IL-18

Figure 5. IL-18 Activation and Release. Activation of an Inflammasome yields an active Caspase-1 that
is able to cleave Pro-IL-18 into its active form, IL-18. Secretion out of the cell is mediated by either
release out of an intact cell membrane through a pore (shown here), or via cell membrane rupture, as
during cell death.
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While constitutive synthesis exists in the aforementioned cells, synthesis of IL-18
induced by stimuli is partially controlled by the transcription factor Nuclear Factor kappalight-chain-enhancer of activated B cells, commonly NF-κB (41). Naturally then, a wide
array of stimuli that converge upon the activation of NF-κB, including microbial and
endogenous products binding to the Toll-like receptor (TLR) family, cytokines, and the
antigen receptors T-cell Receptor (TCR) and B-cell Receptor (BCR), result in an increase
in IL-18 production. Of note, the kinetics of IL-18 induction after TLR stimulation are
different from IL-1β. Lipopolysaccharide (LPS) activation of TLR4 showed IL-18 levels
reach maximal level at 8 hours and remain elevated at 24 hours, whereas IL-1β reaches
maximum levels at 4 hours and decrease by 24 hours (42).
Once produced, activated, and secreted, IL-18 diffuses locally and is capable of
acting in autocrine, paracrine, and endocrine fashions. With resemblance to IL-1β
signaling, a heterodimeric receptor complex mediates conversion of the extracellular IL18 signal to an intracellular response(43). Depicted in Figure 6 below, the two proteins that
complement each other to facilitate binding and signal transduction are IL-18Rα and IL18Rβ. The alpha chain is expressed on a broad array of cell types, possess low affinity
for IL-18, and alone is non-responsive to IL-18 in vitro (43–45). In contrast, the beta chain,
known also as an accessory protein, is expressed in lung, spleen, prostate, small
intestine, peripheral blood T cells and NK cells and has higher affinity for its IL-18
substrate (45). Alone, each receptor is unable to activate NF-κB or c-Jun N-terminal kinase
1 (JNK1, a regulatory protein for gene transcription); however, in combination the
receptors elicit strong NF-κB and JNK1 activation (45). Additional intricacies of the IL-18
receptor complex, responsible for the research here, are discussed later.
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Due to partial cytoplasmic homology of the IL-1 and IL-18 receptors, it is no
surprise the two provoke a similar intracellular response (43). Intracellular cascades
consist of myeloid differentiation primary response 88 (MyD88) recruitment to the receptor
tail, IL-1 Receptor-Associated Kinase (IRAK) and TNF receptor associated factor 6
(TRAF6) interaction, and eventual NF-κB activation (46–48). Distinct again from IL-1
signaling is the additional activation of mitogen-activated protein kinase (MAPK) and
signal transducer and activator of transcription 3 (STAT3) with IL-18 stimulus as
evidenced by in vitro studies of NK cell lines (49).
Also integral to net IL-18 signaling are the soluble circulating endogenous protein
isoforms, known as IL-18 Binding Protein (IL-18BP), that bind free extracellular IL-18 in a
1:1 ratio and remove it from the pool of available and functional IL-18 (50). Constitutively
secreted at levels approximately 20 times that of IL-18 and with high affinity for IL-18, IL18BP functions seemingly as a natural balance to the activation of the T helper cell
response to prevent a detrimental autoimmune cycle (51–53).

15

IL-18BP
IL-18

α

IL-18

β

MyD88
IRAK4
TRAF6
JNK1
MAPK
STAT3

NF
κB

IκB

Pro-inflammatory
Gene transcription

Figure 6. IL-18 Binding and Signaling. Once in the extracellular space, free and active IL-18 (not bound
to circulating IL-18BP) binds to its receptor complex composed of, at least, IL-18Rα and IL-18Rβ.
Activation of the receptor complex leads to intracellular cascades including the activation of MyD88,
IRAK4, TRAF6, JNK, MAPK, STAT3, and NF-κB, which facilitate transcription of genes involved in
numerous cell functions, including inflammation.
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IL-18: Functions
Role of IL-18 in the Immune System
The uniqueness and complexity of IL-18 biology is derived from its pleotropic
effects on multiple cells and organ systems as well as the intricate balance between
homeostatic and pathologic functions. In regards to the immune system, IL-18 has its
hand in innate, adaptive, and autoimmunity; responsible for activation and/or
differentiation of multiple cell types including macrophages, naive T cells, NK cells, and
B cells (54). Specific cytokine environments coordinate and specialize immune cell
responses and contribute to acute disease states (such as myocardial infarction,
microbial invasion of the gut, and skin lesions), chronic disease states (such as heart
failure and Type II diabetes mellitus) and genetic mutations (macrophage activation
syndrome) (54–56).
Inflammation is an evolutionarily refined process initiated by the immune system
designed to clear local and global pathogen or damage insults and best attempt to restore
tissue to its previous functional state. The ability of IL-18 to induce chemokine production
to attract neutrophils (57), increase endothelial Intercellular Adhesion Molecule-1 (ICAM1), Vascular Cell Adhesion Molecule-1 (VCAM-1), and E-Selection expression (58, 59), and
stimulate production of IL-6 and IL-1β place it central to initiation and propagation of
inflammation in various disease states (60). Innate immune cell products, such as IL-18,
serve also to bridge the innate and adaptive immune responses. Pathogen associated
molecular patterns (PAMPs), such as lipopolysaccharide or bacterial DNA, or damage
associated molecular patterns (DAMPs), such as extracellular ATP or mitochondrial DNA,
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bind to a family of pattern recognition receptors (PRRs) that include the Toll-Like
Receptors (TLRs). Binding of ligands to TLRs present on neutrophils and macrophages
initiates intracellular cascades leading to production of cytokines, including IL-18.
Interleukin-12 importantly acts to increase plasma membrane IL-18Rα levels in CD4+ T
cells, rendering the naïve T-cells able to bind extracellular IL-18. Binding of Il-18 to the
IL-18 receptor complex and subsequent intracellular cascades culminate in transcription,
translation, and release of INF-γ from the T-cell (61). IL-18 induced release of INF-γ further
results in activation of macrophages to begin a pro-inflammatory feedback mechanism to
amplify IL-18, IL-1β, and TNF-α levels, the defining characteristics of the Th1 response
(62).
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Role of IL-18 in the cardiovascular system: Health and Disease
Little evidence exists for the function of IL-18 in homeostasis and preservation of
the myocardium or vasculature. The identification of pro-inflammatory cytokines,
including IL-18, as factors associated with

diseases such as hypertension,

atherosclerosis, myocardial infarction, and heart failure has been studied extensively in
the clinical and pre-clinical realms.

Hypertension
Hypertension is now present in approximately 46% of U.S. adults with varying
etiologies (63). In response to prolonged hypertension, the myocardium undergoes
physiologic hypertrophy to decrease wall stress and oxygen consumption in order to
continue ejecting adequate volumes of blood without entering into an ischemic state ( 64).
However, sustained pressure overload tips the physiologic hypertrophic adaptation to
pathologic as further hypertrophy stiffens the ventricle, impairs coronary circulation, and
can lead to arrhythmias. Evidence of this hypertrophy discovered on electrocardiographic
or echocardiographic assessment is an independent risk factor for future cardiovascular
morbidity and all-cause mortality (65–67).
Clinical correlations and basic science investigation have identified IL-18 to be
involved in the hypertrophic response (Figure 7, below). In patients, increased circulating
IL-18 is correlated with hypertension as well as left ventricle mass (68). In a mouse model
of pressure overload induced by thoracic aorta constriction (TAC), the genetic deletion of
IL-18 (IL-18KO) resulted in less hypertrophy than wild-type control; however, was
accompanied by worse LV contractility, indicating that in response to pressure overload
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IL-18 is necessary to some degree for hypertrophic adaptations (69). A molecular pathway
identified in hypertrophy induced by IL-18 is the PI3K→Akt→GATA4 signal that leads to
transcription of genes including atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP), and β-myosin heavy chain (MHC), presumably to combat pressure overload (70,
71).

In vitro, cyclical mechanical stress of cardiomyocytes increases mature IL-18 that is

blunted with neutralizing antibodies or IL-18BP while in vivo, pressure overload increased
myocardial IL-18 mRNA and protein, but decreased IL-18BP mRNA and protein (71). To
further support the notion of IL-18 directly involved in the hypertrophic response, daily
administration of IL-18 to young healthy mice induced left ventricular wall thickness and
diastolic dysfunction (72,73). The expanding understanding of IL-18 in mediating
hypertensive induced cardiac remodeling places further investigation of IL-18 signaling at
the forefront of cardiovascular research.
Diastolic
Dysfunction

Hypertension

IL-18

PI3K

Akt

Impaired
coronary
circulation

GATA4

ANP, BNP

β-MHC

Arrhythmias
Independent
mortality
risk factor

Figure 7. Hypertrophic Adaptation and IL-18. IL-18 is capable of signaling cascades leading to
physiologic hypertrophy and diuresis to adapt to elevated afterload. Sustained hypertrophy; however,
impairs ventricular function and increases mortality risk.
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Atherosclerosis
Atherosclerosis is increasingly defined as an inflammatory disease. Disease
progression is characterized by damaged endothelium, due to shear stress
(hypertension), oxidative stress from increased lipid metabolism (hyperlipidemia) or
cholesterol accumulation (hypercholesterolemia), that attracts neutrophils to hone and
activate macrophages and T lymphocytes that amplify local inflammation resulting in
advanced complicated lesions in vessel walls (74,75). IL-18 has an integral role in gradual
progression of lesions as well as the latter stages of plaque instability and rupture (Figure
8, below). Endothelium that has accumulated low-density lipoproteins and its derivatives
are prone to oxidative stress and release of cytokines. IL-18 induced increases in
adhesion molecules (ICAM-1) on the plasma membrane of the endothelium promote
monocyte and T-cell adhesion and extravasation into the vascular intima where lipids are
accumulating.
The aforementioned combination of local IL-12 and IL-18 drive the differentiation
of naïve T-cells into the Th-1 phenotype to produce INF-γ within the vascular intima.
Macrophage activation via INF-γ polarizes that cell line to a pro-inflammatory state,
deemed the M1 response. Macrophages become significant local effector cells
contributing to smooth muscle cell proliferation, necrosis of the plaque core, and extracellular matrix breakdown (76). Unstable/symptomatic plaques have shown increased
levels of IL-18mRNA compared to stable/asymptomatic plaques in patients (77). Inhibition
of IL-18 with an IL-18BP expression plasmid decreased lipid deposition, macrophage and
T-lymphocyte infiltration, and increased collagen content in mice, further indicating that
IL-18 is involved in plaque development and stability (77,78).
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Accumulation of lipids
in intimal wall

• IL-18 contributes to a
pro-inflammatory cycle
that leads to plaque
expansion, necrosis, and
instability

• Oxidative stress
damages
endothelium which
releases IL-18
• IL-18 causes
leukocyte,
monocyte, and Tcell attraction and
adhesion

Figure 8. Atherosclerosis and IL-18. Initial LDL and lipid accumulation within the vascular intimal wall
occurs over a prolonged period. Extended exposure of endothelial cells to lipids results in oxidative
stress, endothelial damage, and initiation of pro-inflammatory cascades, including IL-18, which recruits
immune cells to the damage site. Local inflammation is amplified and leads to cell death within the plaque
core and proliferation of surrounding smooth muscle cells that further narrow the vessel. Exacerbation
past this point can create symptomatic ischemia with exercise or at rest.
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Myocardial Infarction
After plaque rupture, coronary vessel occlusion, and myocardial ischemia, the
crosstalk between immune cells and surviving myocytes and fibroblasts is essential to
best repair the cardiac tissue. While essential to a degree, prolonged and exaggeration
of this response is detrimental as it continues to destruction of remaining cardiomyocytes,
expands infarct size, and accelerates the progression to heart failure ( 79). If the immune
system response teeters the myocardium on the delicate balance between repair and
worsening prognosis, it comes logically that suppression of an exaggerated immune
response could be beneficial (80). While IL-1β has received more investigation and
therapeutic attention in this setting, IL-18 is also a key player.
After ischemia reperfusion in the mouse, cardiac, endothelial, and smooth muscle
cell IL-18 mRNA is increased, as well as serum IL-18 levels (81,82). Pre-treatment with an
IL-18 neutralizing antibody or injection of mesenchymal stem cells overexpressing IL18BP into the coronary artery of mice reduced infarct size and improved ejection fraction
(82,83). The cardiodepressant effects of IL-1β have been shown to be mediated by
induction of IL-18, as IL-18KO mice treated with IL-1β did not have reduced fractional
shortening compared to wild-type mice treated with IL-1β (32). Therefore, where treatment
with IL-1R blockade improves cardiovascular outcomes in patients with previous
myocardial infarction (MI), and IL-1 effects are in part mediated by IL-18, it is possible
that inhibition of IL-18, either with exogenous binding protein or neutralizing antibody,
could also be a treatment that yields meaningful clinical benefits to patients who achieved
reperfusion after MI (84).
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Heart Failure
Regardless of etiology, a staple of a failing heart is damaged or stressed
myocardium that recruits and activates effector immune cells (79). Cytokine signaling
between immune, fibroblast, endothelial, and cardiac cells induces altered calcium signal
coordination, oxygen free radical damage, apoptosis, and myofibroblast expansion that
combine to impair systolic and/or diastolic function and manifest as clinically relevant
symptoms (85).
Clinical and basic science observations have identified elevated IL-18 to be
associated with worsening heart failure functional class and involved in the pro-fibrotic
response that contributes to diastolic dysfunction (86, 87). Carbone et. al. have shown that
IL-18KO mice on a high-saturated fat diet have preserved diastolic function despite
greater obesity (86). In a rat model of metabolic syndrome and IL-18 overexpression,
worsened diastolic dysfunction but preserved ejection fraction was noted (88).
A classic characteristic of heart failure is over activation of the sympathetic nervous
system (SNS) that attempts to compensate for a failing heart’s inability to perfuse tissue
as it once could. The interplay between sympathetic activation and ensuing immune
activation that perpetuates a failing heart, specifically involving IL-18, has been
investigated in humans and mice (Figure 9, below). After noting an association between
increased serum norepinephrine and IL-18 in patients with non-ST-segment elevation
myocardial infarction (NSTEMI) or unstable angina, Xiao et. al. observed that acute overactivation of β-AR receptors with isoproterenol in mice induced myocardial IL-18 and
macrophage infiltration (89). Blockade of IL-18 using antibodies reduced chemokine,
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adhesion molecule, and pro-inflammatory cytokine gene expression, as well as reduced
cardiac inflammation, fibrosis, and improved functional parameters (89).
Additionally involved in the circulatory system’s response to heart failure is
activation of the renin-angiotensin-aldosterone system (RAAS), again in attempt to
maintain cardiac output by retaining Na+ and arterial vasoconstriction. There is increasing
evidence of hormonal (Angiotensin II) and inflammatory (IL-18) convergence onto
pathways causative of diastolic dysfunction. Angiotensin II increases myocardial fibrosis
in mice, partially through production of Osteopontin (OPN). OPN is a protein secreted by
macrophages, fibroblasts, and myocytes into the extracellular space that is critical to
collagen synthesis and deposition, as well as myofibroblast differentiation (90). IL-18
administration to mice has also been shown to increase OPN levels, along with
myocardial fibrosis, collagen, and ventricular stiffness (Figure 9, below) (91).
In summary, basic science models and patient cohorts have represented IL-18
involvement in development and worsening of cardiovascular diseases including
hypertension, atherosclerosis, myocardial infarction, and heart failure. Further
clarification of IL-18 pathways may pay great dividends going forward for patients at risk
for and those who have already developed the aforementioned diseases.
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Figure 9. IL-18 and diastolic dysfunction. Overexpression of IL-18 and induction of the protein
Osteopontin (OPN) leads to fibrosis and diastolic, while genetic knockout of IL-18 in a model of diet-induced
obesity preserved diastolic function and reduced fibrosis ( 80). Stimulation of β-Adrenergic receptors with
isoproterenol induces immune cell recruitment and diastolic dysfunction that was preserved with antibody
blockade of Il-18 (82).
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Role of IL-18 in metabolism: Health and Disease
The complicated nature of IL-18 signaling in metabolism is in part due to
contrasting physiological observations. In the early 2000’s, clinical correlations between
circulating IL-18 levels and obese and diabetic patients were made. Compared to healthy
volunteers, patients with type 2 diabetes mellitus had higher serum IL-18 (92). Obese
women were also found to have higher serum IL-18 levels that positively correlated with
BMI, waist-to-hip ratios, and negatively correlated with insulin sensitivity (93). Acute
hyperglycemia in healthy and glucose intolerant patients showed an increase in IL-18
levels that was prolonged in patients with impaired glucose tolerance (94). A separate
study incorporating a large community population indicated a consistent graded
relationship between plasma IL-18 and odds ratio for metabolic syndrome (95).
This discovery of IL-18 positively correlating with the metabolic syndrome in
patients has led to a growing number of preclinical investigations. Early evaluation by
Netea et. al. in IL-18KO mice showed the spontaneous development of obesity and insulin
resistance at 6 months of age that was preceded by increased chow intake (hyperphagia)
(96). Supporting data by Zorrilla et. al. again showed that IL-18KO mice developed a
phenotype of increased body weight and adiposity preceded by increased standard chow
or high fat diet intake, as well as an increased respiratory exchange ratio (RER) ( 97,98).
Collectively, these initial results indicated that although clinical data suggested a
pathophysiologic association of IL-18 in the development of the metabolic syndrome, the
genetic absence of IL-18 was also able to produce a phenotype of obesity and insulin
resistance.
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Recent work has further implied IL-18 to be essential to body weight and glucose
homeostasis through catalytic activation by the NLRP1 inflammasome in the mouse.
Collectively, Murphy et.al. was able to show NLRP1’s ability to respond to energy intake
and coordinate metabolic homeostasis, specifically through IL-18 (99).
Interestingly, administration of recombinant IL-18 (rIL-18) to mice via intravenous
administration had no effect on food intake while intracerebral administration significantly
reduced food intake, suggesting the effect of IL-18 on food intake may occur within the
central nervous system (CNS) (96,98). After elegant work discovered precise neurocircuit
elements responsible for feeding behavior in the lateral hypothalamus (LH), the central
effects of IL-18 on appetite were further investigated (100,101). It was discovered that IL-18
altered neuron activity in the (LH) to result in decreased food intake in mice (101).
Peripherally, IL-18 administration to mice has been shown to slightly increase
insulin sensitivity, increase 5’ AMP-activated protein kinase (AMPK), and increase fatty
acid oxidation (96,102). Additionally, rIL-18 administration to mice decreased body weight
and improved lipid handling capacity of the liver (103). Thus, an overall divide of IL-18
metabolic contributions between the CNS to regulate food intake and the periphery to
positively alter insulin sensitivity and lipid metabolism has been discovered (Figure 12).
The apparent negative contributions of IL-18 to cardiovascular disease mixed with
possible positive influences on metabolism, namely decreased food intake and improved
glucose/lipid metabolism, create an unclear therapeutic potential of IL-18. On one hand,
inhibition of IL-18 signaling at the myocardium appears beneficial, as it has been shown
to attenuate cardiac dysfunction. However, genetic absence of IL-18 in mice leads to overt
obesity and T2D. Thus, an apparent disconnect in IL-18 signaling exists (Figure 12).
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Similarities and differences in IL-18KO and IL-18RαKO mouse phenotypes: A role
for the Na-Cl Co-transporter?
As discussed before, deletion of the ligand IL-18 (IL-18KO) results in a phenotype
of obesity and T2D (96,98). However, mildly differing phenotype results have been
observed after the genetic deletion of the IL-18Rα, responsible for binding IL-18. IL18RαKO mice display hyperinsulinemia and decreased glucose tolerance akin to IL-18KO
mice; however, regardless of diet, they exhibit body weight changes and food intake
levels that resemble wild-type mice more than IL-18KO mice (Figure 10) (102, 104).

Figure 10. IL-18KO and IL-18RKO divergence. Adapted from Lindegaard et al Diabetes 2013 and
Pazos et al Scientific Reports 2015. (Top) Body weight gain on either standard diet (SD, CH, chow) or
high-fat diet (HFD) of wild-type, IL-18RαKO, or IL-18KO mice. Apparent is the trend that IL-18RαKO mice
do not have a growth pattern that is alike IL-18KO mice. (Bottom) Chow or HFD food intake of wild-type,
IL-18RαKO, or IL-18KO mice. Again, the IL-18RαKO mice do not exhibit hyerphagia like IL-18KO mice.
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Additionally, peripheral disconnects in IL-18 signaling have been shown in the
context of atherosclerosis. In a mouse model of atherosclerosis, IL-18RαKO was unable
to decrease plaque size in vivo or prevent IL-18 binding to isolated endothelial cells ex
vivo. A cell surface binding alternative for IL-18 was found to be the 125 kDa Na-Cl Cotransporter (NCC) (105). The distal convoluted tubule (DCT) apical transmembrane protein
is known to be responsible for ~5% of Na+ reabsorption in the kidney and is the target for
thiazide-type diuretics that are considered to be part of first-line therapy for hypertensive
patients (106,107).
Further investigation yielded that IL-18 had strong binding affinity for NCC, and IL18 treatment in vitro to cells expressing NCC and not IL-18Rα increased protein tyrosine
phosphorylation, indicating a signal is transduces across the plasma membrane due to
IL-18 binding to NCC. Genetic changes in the mouse model of atherosclerosis yielded
further support to in vitro IL-18/NCC communication observations. Decreases in
atherosclerotic lesion are were only observed in the double knockout of Apoe−/−NCC−/−IL18Rα−/− and not in Apoe−/−NCC−/− or Apoe−/−IL-18Rα−/− backgrounds (Figure 11, below).
Combined, these results indicated that the membrane localized Na-Cl Co-transporter
effectively played a role in mediating atherosclerosis through IL-18 signaling in the
mouse, suggesting that NCC may also mediate other physiologic processes where IL-18
signaling is important, possibly including metabolic and cardiac function discussed
previously.
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Figure 11. NCC in Atherosclerosis. Adapted from Wang et al Nature Medicine 2015, Aortic root lesion
intima area in different genetic backgrounds. Where Apoe−/−NCC−/− or Apoe−/−IL-18Rα−/−
backgrounds are not protected from atherosclerosis, Apoe−/−NCC−/−IL-18Rα−/− significantly decreases
aortic lesion area intimal area. These results implicate NCC as a receptor in physiologic processes where
IL-18 activity is involved.

Thus, further understanding the mechanism by which IL-18 signaling is achieved
may reveal intricacies to its biology, role in homeostasis, and metabolic and cardiac
disease as well as open therapeutic doors (Figure 12, below). The major goal of the work
presented here, and still underway, is aimed at unraveling the role of NCC as a coreceptor for IL-18 signaling in metabolic and cardiac function by investigating the genetic
knockout of NCC in a mouse model of high-fat diet induced obesity.
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Figure 12. IL-18 Physiology. The complex interplay of IL-18 and its contributions to immune,
cardiovascular, and metabolic function. Within the immune system, IL-18 mediates communication
between cell types to specialize the immune response toward a pro-inflammatory state. In the vascular
system, IL-18 functions between endothelial, macrophages, and T-cells to promote atherosclerosis.
Within the heart, IL-18 can induce cardiomyocyte hypertrophy and fibroblast collagen deposition that
contribute to diastolic dysfunction. The effects of IL-18 on metabolism are less clear-cut, but include
decrease food intake within central nervous system and possible positive modulation of glucose and lipid
metabolism in the periphery at adipose and skeletal muscle tissue. The role of NCC as a receptor that
mediates these functions is investigated here.
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With the comprehensive background of Interleukin-18 being required for
metabolic homeostasis, but able to cause ventricular hypertrophy, fibrosis, and
dysfunction with the capability to act through its co-receptor Na-Cl Co-transporter (NCC)
to elicit function; we hypothesize NCC may act to mediate IL-18 effects on metabolic
and cardiac function. Therefore, the genetic knockout of NCC (NCCKO) will worsen the
metabolic phenotype, but attenuate the cardiac phenotype after western diet feeding.
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Methods
a. Animals
i. All animal experiments were conducted under guidelines on the humane
use and care of laboratory animals for biomedical research published by
the National Institutes of Health. The Institutional Animal Care and Use
Committee (IACUC) of Virginia Commonwealth University approved this
study. Eight- to 12-week-old mice of the C57BL/6J background
genetically modified to lack the gene for the Na-Cl Co-transporter (NCC)
(NCC KO) and IL-18KO mice were purchased from The Jackson
Laboratory (Bar, Harbor, ME).
b. Study Design
i. Prior to diet intervention, NCCKO male (n=10) mice had free access to
standard chow and water. After baseline metabolic and cardiac
assessment, each group was divided so that half of the group (n=5) was
assigned to maintain a standard chow diet (Teklad LM-485; Envigo)
while the other half (n=5) was assigned to maintain a “western diet” (WD)
rich in saturated fat and sugar (Teklad TD.88137; Envigo). A group of
female mice were studied as well to see differences associated with e
gender. However, in this study, only the male mice are reported. IL-18
KO and wild-type (n=10/group) were also fed with WD to be used as
comparison for the NCCKO mice. The study was performed over an 8
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to 16 week period to assess metabolic and cardiac phenotype. Nutrient
composition of each diet is listed in Table 2 below.

Figure 14. Research Design.

Dietary composition
in %kcal

Standard Diet
(SD)

Western Diet
(WD)

Carbohydrate

44.3

42.7

Protein

19.1

15.2

Total Fat

5.8

42.0

Saturated Fat %
of total fatty acids

0.8

61.8

Cholesterol

--

0.2

Kcal/g
(Energy Density)

3.1

4.5

Table 2. WD Composition. Nutrient composition of Standard Diet (SD) and Western Diet (WD).
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c. Food intake and body weight
i. Food intake was measured biweekly as the disappearance of food in
grams (g) since last observation. Body weight was measured weekly
using a scale and recorded in grams.
d. Oral Glucose Tolerance Test (OGTT)
i. Mice were fasted overnight (16 hours) before measurements of fasting
blood glucose. The mice were transferred from their previous cage to
clean cages with no evidence of food or feces in the new cage. Mice had
free access to water during the fasting period. The blood was collected
from the distal tails of the mice. The first drop of blood removed via
gauze pad, and the following drop of blood was used to obtain serum
glucose concentrations with an AimStrip Plus Blood Glucose Meter
(Ermaine Laboratories Inc.) and AimStrip Plus Blood Glucose Test
Strips (Ermaine Laboratories Inc.). Blood glucose concentrations were
measured at baseline after the 16 hours fasting and at time points 15,
30, 60, and 120 minutes after glucose challenge. A 20% by weight D(+)-Glucose (Sigma-Aldrich) solution in water (ex. 2g D-(+)-Glucose in
10mL water) and mice were carefully given 10µL/g body weight via oral
gavage. All the NCC KO mice received the test at baseline and before
the study termination, while the IL-18 KO and wild-type received the test
only at baseline, and fasting glycemia prior to termination. For
consistency, the fasting glycemia is reported for all three groups.
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e. Insulin Tolerance Test (ITT)
i. Mice were fasted for 6 hours before measurements of serum glucose.
The mice were transferred from their previous cage to clean cages with
no evidence of food or feces in the new cage. Mice had free access to
water during the fasting period. Blood was collected from the distal tails
of the mice, the first drop of blood removed via gauze pad, and the
following drop of blood was used to obtain serum glucose concentrations
with an AimStrip Plus Blood Glucose Meter (Ermaine Laboratories Inc.)
and AimStrip Plus Blood Glucose Test Strips (Ermaine Laboratories
Inc.). Serum glucose concentrations were measured at baseline after
the 6 hours fasting and at time points 15, 30, 60, and 120 minutes after
insulin challenge. Stock Insulin (Lantus, insulin glargine injection,
provided by Virginia Commonwealth Division of Animal Resources)
provided was 1 Unit/10µL and the overall administration was to be 1 Unit
Insulin/1kg body weight of mice. The body weight of mice undergoing
testing was summed to find the amount of Insulin Units needed (ex. 20
mice totaling 640g = .64 Units = 6.4µL stock Insulin). Insulin was diluted
in 0.9% Normal Saline (NS) to make the final solution (ex. 20 mice
totaling 640g requires 6.4mL final volume. For simplicity, a solution
containing 10uL stock Insulin within a total 10mL volume with 0.9% NS
as solvent was made).

Mice were given 10µL/g body weight

intraperitoneal injection of the Insulin/Saline solution and blood glucose
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was measured at time points mentioned above. This test was performed
on NCC mice only, therefore the results are not part of the dissertation.
f. Echocardiography
i. Mice underwent transthoracic Doppler echocardiography (Vevo770;
VisualSonic, Toronto, ON, Canada, 30MHz probe) under sedation (3050 mgkg-1 pentobarbital) to evaluate systolic and diastolic parameters at
baseline prior to diet administration, 4, 8, and 16 weeks after the
beginning of either standard or western diet. B-Mode was used to find
mid-papillary region of the left ventricle. M-Mode was then used to
measure left ventricular end-diastolic diameter (LVEDD) and leftventricular end systolic diameter (LVESD), then left ventricle fractional
shortening (LVFS) was calculated [(LVEDD-LVESD)/LVEDD]*100.
Pulse-Wave Doppler was used to assess isovolumetric contraction time
(ICT), ejection time (ET), and isovolumetric relaxation time (IRT).
Myocardial Performance index (MPI), also known as Tei index, an
assessment of global systolic and diastolic function, was calculated as
[(ICT+IRT)/ET].
g. IL-18 ELISA
i. Blood was collected from mice through the inferior vena cava at the time
of death. Blood was incubated in tubes with heparin (BD, Franklin Lakes,
NJ) for 15 min and then centrifuged at 2,000 rpm at 4°C for 10 min to
obtain plasma. Samples were stored at −80°C and subsequently
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analyzed with a specific ELISA for murine IL-18 (plasma, MBL)
according to the supplier's instructions to assess the induction of IL-18
after WD. Absorbance was read with a Bio-Tek plate reader (model
μQuant, Bio-Tek, Winooski, VT) at 450 nm. Data are expressed in
picograms per milliliter (pg/mL).
h. Statistical Analysis
i. For the animal study, because of the low expected variance within the
groups, values are expressed as mean and SEM. The differences
between groups were assessed using analysis of variance followed by
the Student t test for unpaired data to compare the individual groups.
Microsoft Excel and GraphPad Prism 7 were used for statistical
analyses.
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Results:
We set out to evaluate paramters of metabolism and cardiac function in three groups of
mice fed a high-saturated fat diet: Wild-type, IL-18KO, and NCCKO.

WD induces systemic release of active IL-18
To assess the inflammatory state after WD, we measured plasma IL-18 in
NCCKO and wild-type mice on WD and compared them to separate C57BL6/J wild-type
mice that were on standard diet (SD). We observed an statistically significant increase
in plasma IL-18 after WD in wild-type (183.3pg/mL ± 29.3) and NCCKO (237.6pg/mL ±
12.7) mice compared to wild-type mice on SD (79.3pg/mL ± 19.9) (Figure 15).

Figure 15. WD Increases circulating IL-18. Plasma IL-18 measured by ELISA in wild-type mice and
NCCKO mice on WD compared to wild-type mice on SD (n=5-8). Data (in pg/mL) are reported as means
± SE (One-Way ANOVA — P-values vs. wild-type mice on standard diet).
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Body Weight changes over study duration
Plotted in Figure 16 (top), we analyzed absolute body weight (g) at 1 week time
points over the course of 8 weeks for Wild-type, IL-18KO, and NCCKO male mice. All
the mice displayed normal appearance and behaviour. At baseline, IL-18KO mice
weighed significantly more than NCCKO, but not more than wild-type mice. At the later
time points, the IL-18KO mice started to weigh signifincantly more than the wild-type
and maintained a constant difference from the NCCKO (Figure 16, top).
To evaluate rate of growth on WD relative to initial weight in all mouse strains, we
calculated percent change from baseline (%) at each week (Figure 16, bottom). In this
way, we can compare the rate at which the mice gain weight, independent from the
differences at baseline. We found that the IL18KO and NCCKO gain a significantly
larger percentage of weight, 46.4 % ± 4.1 and 55.0% ± 2.1 respectively, than the wildtype mice who gained 21.7% ± 6.8 of initial weight (P<0.05) (Figure 16, bottom). This
data suggests that NCCKO mice on WD gain weight to a greater extent than wild-type
mice that resembles body weight changes observed in IL-18KO mice on WD.
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Figure 16. Increased Body Weight Gain of IL-18KO and NCCKO mice on WD. Absolute body weight
gain (top) and percent body weight change from baseline (%) (bottom) comparisons between wild-type,
IL-18KO, and NCCKO over 8 weeks while on Western Diet (n=5-9). (Two-Way ANOVA — #: P<0.05
NCCKO vs. Wild-type, ^:P<0.05 IL-18KO vs. Wild-Type, *:P<0.05 IL-18KO vs. NCCKO). Data (in g) are
reported as mean ±SE.
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WD induced Type II Diabetic phenotype
In order to assess metabolic function in the three groups of mice before and after
WD consumption, fasting glucose levels were taken. At baseline before WD, IL-18KO
and NCCKO mice had significantly higher fasting plasma glucose levels (93.3 ± 4.4 and
92.6mg/dL ± 5.6 respectively) compared to wild-type mice (78.1mg/dL ±1.7) (Figure 17
left, P<0.05). After WD, the fasting plasma glucose was not different between any
groups (151.9 ± 10.6 vs. 165.4 ± 4.7 vs. 156.4 ± 8.0 mg/dL for IL-18KO, NCCKO, and
Wild-Type respectively, Figure 17 right).

Figure 17. Differences in fasting glycemia before, but not after WD. Fasting blood glucose prior to
western diet (baseline, left) and after 8 weeks (wild-type, IL-18KO) or 16 weeks of western diet (NCCKO)
(right) (One-Way ANOVA, P-values vs. Wild-Type). Data (in mg/dL) are reported as mean ±SE, n=3-10.
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Echocardiographic assessment of systolic, diastolic, and global function
To evaluate the change in cardiac function in the three groups after WD, we
chose to evaluate percent (%) change from baseline in Fractional Shortening (FS),
Isovolumetric Relaxation Time (IRT), and Tei Index. When evaluating FS, NCCKO mice
had a 14% ± 8 decrease in FS, while IL-18KO and wild-type had a 13% ± 4, and 28% ±
5 decrease, respectively (Figure 18, top). The percent decrease from baseline was
significantly less in the IL-18KO group compared to Wild-Type, but not statistically
different between NCCKO and Wild-Type mice. NCCKO mice after WD had a
significantly smaller increase (29% ± 16) in IRT compared to wild-type (123% ± 21),
while the IL-18KO % increase in IRT (67 ± 26) was not statistically significant from wildtype (Figure 18, middle). The percent change in Tei index, a marker of global function,
from baseline was significantly preserved in NCCKO and IL-18KO mice (62% ± 21 and
46 ± 22 increase respectively) compared to the wild-type percent increase from baseline
(162% ± 23 increase, Figure 18, bottom). Collectively, these echocardiographic
changes over time indicate that after WD, NCCKO mice exhibited less worsening of
diastolic and global function compared to wild-type mice that resembled the IL-18KO
phenotype.
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Figure 18. Attenuated changes in cardiac function after WD in IL-18KO and NCCKO mice.
Echocardiographic measurements Fractional Shortening (FS, top), Isovolumetric Relaxation Time (IRT,
middle), and Tei Index (bottom), percent changes from baseline to after western diet completion (wildtype and IL-18KO 8 weeks, NCCKO 16 weeks). One-Way ANOVA test to evaluate trend within groups,
and T-test to evaluate statistical differences between groups: #:P<0.05 vs. Wild-Type. Data (in % change)
are presented as mean ±SE, n=5-9.
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Discussion
The results of the current study show that mice genetically lacking the Na-Cl Cotransporter have an overlapping phenotype with mice genetically lacking IL-18. IL-18
has both cardiodepressant activity and prevents weight gain by suppressing appetite.
NCC is a newly discovered receptor for Interleukin-18, and we hypothesized that it may
in part mediate the negative effects of IL-18 on cardiac function and the positive effects
of IL-18 on metabolic function during WD feeding. After establishing that a WD induces
increased levels of IL-18 in both wild-type and NCCKO mice (Figure 15), we assessed
metabolic and cardiac phenotypes.
To study the role of NCC in metabolism, we used an accepted model of dietinduced obesity whereby mice are fed with a specific diet for at least 8 weeks to induce
metabolic and cardiac dysfunction. The high energy density and high percentage of total
and saturated fat diet used as WD (Western Diet) is advantageous in this basic science
investigation due to its high relevance to consumption habits in western populations.
NCCKO mice appear to be smaller than the IL-18KO mice at any weekly interval.
However, to better evaluate weight gain while on the diet, the weight gain was
measured and normalized by the initial weight (Figure 16, bottom). Evidently, the rate of
body weight increases from baseline of the NCCKO mice on WD (55% at 8 weeks) has
striking resemblance to the rate of body weight increase of IL-18KO mice on WD
(46.4% at 8 weeks) where both groups gained significantly more weight relative to
baseline than wild-type mice on WD (21.7% at 8 weeks). This is of importance when
compared to available literature that has investigated body weight gain of IL-18RαKO
mice. Two groups have observed a pattern whereby the IL-18RαKO mice growth rate
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on a WD is slower than that of IL-18KO and more closely resembles that of a wild-type
mouse on WD (Figure 10, Introduction) (102,104). The trend of acute onset and sustained
obesity while on WD in mice lacking IL-18 or an upstream activator such as NLRP1 or
TLR4 is well-documented in the literature (98,99,104,108).
Our observations indicate that perhaps during a state of high-saturated fat
feeding which induces a low-grade pro-inflammatory state, IL-18 may be signaling in the
brain to control appetite and in the heart to regulate relaxation to a greater degree
through NCC rather than the IL-18Rα. Support for IL-18 “favoritism” to NCC has been
observed in vitro. Conjugated IL-18 showed a higher binding affinity to NCC than to IL18Rα [NCC dissociation constant (a concentration that indicates when 50% of binding
has occurred) Kd = 17.3nM vs. IL-18Rα Kd= 46nM] (51,105). Additionally, IL-18 has been
shown to increase peritoneal macrophage NCC mRNA levels by 65 fold, as well as
increase plasma membrane NCC in macrophages and T-cells treated with IL-18,
observable by immunostaining (105). It is possible, but has not been analyzed to our
knowledge, that IL-18 may cause a similar increase in NCC within neural tissue that
becomes primarily responsible for binding to IL-18 and modifying neural circuits to
decrease satiety and eventual body weight.
Importantly, this hypothesis would necessitate careful investigation of food
intake. A common method of measuring food intake is to measure the disappearance of
food from the mice cages; however, this measurement has high variability due to the
fact that mice “play with” the sticky texture of the high-saturated fat diet and do not
necessarily ingest all of the WD that disappeared from the previous measurement. This
method was attempted with these groups of mice, but the pitfall of the measurement
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tool limited the accuracy of the data. A more precise method of measuring food intake
using a metabolic chamber is in planning to best evaluate physiologic changes in food
intake in similar groups studied here.
It cannot be understated that a key component of IL-18 signaling in positively
affecting metabolism is within the central nervous system (CNS) to decrease appetite
and food intake. Common to pro-inflammatory states of non-specific illness is the loss of
appetite(109). Interleukin-18 has been identified in the mouse to contribute to this
phenomenon. Through a pre-synaptic disinhibitory mechanism, IL-18 disrupts the
balance of excitatory and inhibitory electrical signals in the amygdala that culminates in
increased lateral hypothalamic (LH) firing and a decrease in food intake (101). An
observed reduction in standard diet food intake after central IL-18 administration was
deemed to be dependent on the presence of the IL-18Rα as brain slices from IL18RαKO mice treated with rIL-18 did not exhibit significant changes in electrical
properties changes as seen in brain slices from IL-18Rα+/+ mice. However, these
experiments were done in IL-18RαKO mice 3-5 months of age on a standard diet. Mice
on a standard diet have been shown to have significantly less (approximately 30%)
plasma IL-18 than mice fed a WD for 8 weeks (86). Additionally, the ELISA results
shown here indicate circulating IL-18 approximately doubles after WD (Figure 14). It is
possible the IL-18Rα+/+ and IL-18RαKO mice fed standard diet, and studied specifically
for IL-18/IL-18Rα mediated hypophagia, did not have sufficiently elevated IL-18 levels to
induce relevant NCC expression within the amygdala and hypothalamus, therefore NCC
function as a receptor could not have been evaluated in that setting.
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Additionally, our analysis of the obese phenotype through weight gain is not as
holistic as appears in other literature that separates body composition by fat mass and
fat-free mass with the use of sophisticated tools such as dual energy X-ray
absorptiometry (DEXA) or EchoMRI. A possible relevancy of accurately measuring body
mass composition to the NCCKO mice here is a finding of increased bone mineral
density (BMD) in NCCKO mice compared to NCC+/+ mice. However, despite an
increased BMD, the absolute weight of littermate NCC-/- and NCC+/+ mice was indifferent
(25.7g vs. 25.9g respectively) (110). More specific tools, while more expensive, could
have elucidated more intricacies of fat and lean mass within the obese phenotypes
observed.
To assess whole body glucose metabolism we measured overnight fasting
plasma glucose levels before and after WD. Prior to the start of WD the IL-18KO and
NCCKO mice had significantly higher fasting glucose (93.3 and 92.6mg/dL respectively)
compared to wild-type mice (78.1mg/dL) (Figure 17, left). Although these levels are still
within a normal range, they indicate that IL-18 and NCC are directly or indirectly
important for glucose homeostasis. Similar observations have been identified for IL18KO mice where, by 3 months of age IL-18KO mice have elevated fasting insulin and
decreased tolerance to glucose and by 6 months of age exhibit full-fledged Type II
Diabetes characterized by elevated fasting glucose, decreased glucose tolerance, and
decreased insulin sensitivity (96).
Peripheral homeostatic functions of IL-18 that relate to energy metabolism are
not well understood. In patients, elevated plasma IL-18 are positively associated with
BMI, Type II Diabetes (T2D), and waist-to-hip ratios, and negatively correlated with
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insulin sensitivity (93 111). This could reflect another phenomenon seen in obese patients
of IL-18 resistance. Leukocytes isolated from obese or T2D patients have a blunted
production of INF-γ in response to IL-18 stimulation that was accompanied by a 50%
reduction in plasma membrane Il-18Rα and IL-18Rβ (112). Interestingly though,
intraperitoneal recombinant IL-18 was able to improve insulin sensitivity in IL-18+/+ and
IL-18-/- mice (96). Additionally, in vitro and ex vivo studies have shown that exogenous
IL-18 treatment increases AMPK and fat oxidation (102). AMPK is an intracellular protein
that coordinates a multitude of cellular functions, including fatty acid uptake, β-oxidation,
translocation of GLUT-4 vesicles to the plasma membrane, promotion of glycolysis and
inhibition of gluconeogenesis, providing further support for IL-18 acting in part to
improve glucose metabolism (113).
Although no other basic science studies to our knowledge have investigated the
effects of NCCKO on glucose metabolism, two potential clinical correlations can be
made. A possible link that has been made for the development of glucose intolerance
and insulin resistance in patients with genetic mutations in NCC, clinically named
Gitelman Syndrome, or hypokalemia in patients receiving thiazide diuretics
(hydrochlorothiazide, chlorthalidone: NCC blockers). Gitelman Syndrome patients and
patients on thiazide diuretics may exhibit hypokalemia owing to increased urinary K+
excretion in the distal tubule and collecting duct (114). Thiazide-induced dysglycemia is a
well-observed phenomenon, but the mechanism behind it is unclear. Speculation to this
point focuses on K+ mediated release of insulin by pancreatic β-cells, but it is not
established as to whether small decreases in K+ are physiologically relevant to cause a
decrease in insulin secretion that results in hyperglycemia (115).
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Connecting apparent findings of IL-18 improving insulin sensitivity, and NCC
acting as a receptor for IL-18 binding and effects, it is possible that IL-18 functions
through NCC to improve insulin sensitivity, although this requires much further
investigation. Although we see higher fasting plasma glucose at baseline in the NCCKO
and IL-18KO compared to wild-type, WD over time does not worsen glycemia, indicating
glucose metabolism during high-fat diet may be independent of IL-18 and NCC function
(Figure 17, right). This finding is somewhat dissociated from the severity of obesity
development. Despite gaining significantly more weight than wild-type, NCCKO and IL18KO display similar fasting glycemia. Future investigation into glucose metabolism and
insulin function is of interest in the NCCKO genotype to perhaps investigate
contributions of electrolyte abnormalities and/or IL-18 mediated effects to alterations in
glucose metabolism.
To evaluate the contribution of NCC to cardiac function during WD, we assessed
systolic, diastolic, and global function parameters via echocardiography. We report
percent change in cardiac function of groups to normalize for baseline differences and
specifically evaluate the effect of the WD on changes in cardiac function. For all three
groups there was decline in fractional shortening (FS) with only the IL-18KO group
having less worse FS changes after WD compared to wild-type mice (13% vs 28%
decline respectively) (Figure 18, top), indicating systolic function was not statistically
preserved by genetic deletion of NCC after WD. This result was somewhat expected as
the model of diet induced obesity induces mild systolic dysfunction, but may retain an
ejection fraction that is still considered preserved.
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Pulse wave Doppler measurements allowed for analysis of diastolic and global
function, specifically isovolumetric relaxation time (IRT) and Tei Index (or Myocardial
Performance Index). For orientation, an increase in IRT or Tei Index indicates
worsening function. In terms of changes in the early relaxation of the left ventricle after
WD, NCCKO mice had significantly attenuated percent changes from baseline
compared to Wild-Type (29% vs. 123%), whereas the IL-18KO percent change from
baseline was not significantly less than the Wild-Type (67% vs. 123%) (Figure 18,
middle). Further support for a less severe effect of WD on cardiac function for NCCKO
mice is supported by a statistically lower percent increase from baseline in global
evaluation via the Tei Index. After WD, both the IL-18KO and NCCKO mice had
significantly lower percent increases in Tei Index (46% and 62% increase respectively)
compared to wild-type mice (162% increase), indicating that the WD had less of a
cardiodepressant effect in the IL-18KO and NCCKO groups (Figure 18, bottom).
Collectively, the echocardiographic results indicated that IL-18 induced by WD may
have a greater impact on diastolic function, and the genetic knockout of IL-18 or the
NCC receptor for IL-18 resulted in less worsened diastolic dysfunction from baseline
after WD.
Keeping in mind clinical heart failure relevancies, a large clinical study evaluating
efficacy of differing anti-hypertensive pharmacotherapy in high-risk hypertensive
patients discovered that the use of a NCC blocker, Chlorthalidone, significantly reduced
the risk of heart failure at 4-8 year follow up compared to an ACE inhibitor (Lisinopril) or
a Calcium-Channel Blocker (Amlodipine) (107). This finding represents a possible link to
the research investigated here, whereby inhibition of NCC aside from the primary goal
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of diuresis to control blood pressure may also be provide direct inhibition of IL-18
signaling in the myocardium to prevent or slow the progression of cardiac dysfunction.
This line of thinking is of high interest that we aim to investigate further in the future.
An alternative method to evaluate novel contributions of NCC to IL-18 signaling
could have been through the use of pharmacologic inhibitors of the ion transporter that
are commercially available, notably hydrochlorothiazide (HCTZ). A flaw to this design
are reports that HCTZ does not cross the blood brain barrier and therefore centrally
mediated effects of NCC may not be able to be assessed; however, this could have
been acutely overcome with direct intracerebral administration of HCTZ via cannulas
placed into the skull and brain (120). This direct central administration method is
complicated; however, by post-surgical induction of pain, distress, and risk for infection
(121). Additionally, although the genetic knockout of NCC has yet to result in embryonic
lethality to our knowledge, NCC has important other physiologic contributions. As noted
prior, the Na-Cl Co-transporter is partially responsible for electrolyte homeostasis,
particularly K+, Mg2+. Therefore, a temporally controlled inducible mutation of SLC12a3,
the gene encoding NCC, in mice could prove to be a beneficial model to study the
physiology related to NCC in the future.
A separate limitation of this study is the fact that the wild-type mice are not
littermates to the NCCKO or IL-18KO mice. Although all of the mice studied have the
same C57Bl6/J background, this is of great importance when attempting to control for a
single genetic change and we cannot exclude the effects of other compounding genetic
alterations when assessing the data. Moreover, genetic knockout mice remain inbred,
which can lead to reduced biological fitness of the population.
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The strength of research presented here derives from the novel findings,
specifically regarding the possible role of the Na-Cl Co-transporter (NCC) in mediating
IL-18 effects on metabolic and cardiac function. We believe the investigation and results
here have laid a foundation for a more elaborate research plan designed to
comprehensively investigate the known components of IL-18 signaling in a similar
experimental model. Others have described that protection from the pro-inflammatory
disease of atherosclerosis is observed only after combined genetic knockout of IL-18R
and NCC (IL-18Rα-/-NCC-/-), and not singular littermate knockouts of either (IL-18R-/- or
NCC-/-) (105). Although the data presented here investigates the sole knockout of NCC,
in the future we hope to replicate the double knockout design and further investigate IL18 signaling mechanisms in the context of diet-induced obesity. In order to accomplish
this, crossbreeding to obtain littermates with differing components of the IL-18 signaling
system missing must be done. Crossbreeding and genomic analysis is currently
underway to establish these mouse lines in preparation for future studies.
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